IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma

Trial Details

NCT ID
NCT06819293
Phase
PHASE1
Sponsor
Grit Biotechnology
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • IB-T101 injection
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
  • Age ≥18 years old;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
  • Expected survival time of ≥ 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →